Going Beyond EXTREME in Head and Neck Cancer

Slides:

Advertisements

Similar presentations

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Advertisements

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evolving Paradigms in Recurrent/Metastatic SCCHN

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Progression After Cancer Immunotherapy in Advanced NSCLC

New Standards of Care in ALK-Translocated Advanced NSCLC

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Activity Goals. Activity Goals Discussion Topics.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Basics of Immunotherapy Potential Therapeutic Targets.

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Advances in Gastrointestinal Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Challenges and Opportunities

Preparing for Checkpoint Inhibitors in Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

Peanut Allergy Immunotherapy

From Adjuvant to Metastatic in Melanoma

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Peanut Allergy Immunotherapy

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Taking a Closer Look at Recurrent/Metastatic SCCHN

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving Care Forward in Advanced Gastric Cancer

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Recent Developments in the Treatment of Advanced and Metastatic RCC

Presentation transcript:

Going Beyond EXTREME in Head and Neck Cancer

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

KEYNOTE-012 Long-Term Follow-Up

CheckMate-141 Phase 3 Trial

CheckMate-141 Results

KEYNOTE-040 Phase 3 Trial

Notes on KEYNOTE-040

Further Notes on Checkpoint Inhibition in the Second Line

PD-L1 as a Biomarker

Use of Biomarkers

KEYNOTE-048 First-Line Trial Trial Design

Use of CPS in KEYNOTE-048

KEYNOTE-048 OS Results of Pembrolizumab Monotherapy vs EXTREME

KEYNOTE-048 Results of Pembrolizumab Monotherapy vs EXTREME (cont)

KEYNOTE-048 OS Results of Pembrolizumab + Chemotherapy vs EXTREME, Total Population

KEYNOTE-048 Results of Pembrolizumab + Chemotherapy vs EXTREME, Total Population (cont)

Notes on KEYNOTE-048

Comparison With Chemoimmunotherapy in NSCLC

Further Notes on KEYNOTE-048

Study Implications

Ongoing Phase 3, First-Line Trials

Thoughts About the Future of Immunotherapy in SCCHN

Abbreviations

Abbreviations (cont)